Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

MorphoSys AG : to Present at Three Investor Conferences in November

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/14/2011 | 03:05pm CEST

MorphoSys AG / MorphoSys to Present at Three Investor Conferences in November . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that management will present at three international investor conferences in November.

9th WestLB Deutschland Conference
Date:                          November 16, 2011 at 10:15am CET (09:15am GMT; 
                                  04:15am EST)
Venue:                        Frankfurt, Germany
Participants:                Jens Holstein, CFO of MorphoSys AG
                                  Dr. Claudia Gutjahr-Löser, Head of Corporate
                                  Communications & IR

Deutsches Eigenkapitalforum
Date:                          November 22, 2011 at 09:45am CET (08:45am GMT;
                                  03:45am EST)
Venue:                        Frankfurt, Germany
Participants:                Dr. Simon Moroney, CEO of MorphoSys AG
                                  Jens Holstein, CFO of MorphoSys AG
                                  Dr. Claudia Gutjahr-Löser, Head of Corporate
                                  Communications & IR

23rd Annual Piper Jaffray Healthcare Conference
Date:                          November 30, 2011 at 01:30pm EST (06:30pm GMT;
                                  07:30pm CET)
Venue:                        New York, USA
Participants:                Dr. Simon Moroney, CEO of MorphoSys AG
                                  Dr. Claudia Gutjahr-Löser, Head of Corporate 
                                  Communications & IR

A PDF version of the Company presentation will be provided at www.morphosys.com/presentations:
http://www.morphosys.com/presentations. Links to the webcast, if available, are filed under www.morphosys.com/conference-calls:
http://www.morphosys.com/conference-calls.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The Company's AbD Serotec unit uses HuCAL and other technologies to generate superior monoclonal antibodies for research and diagnostic applications.

Through its own development efforts and successful partnerships in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline:
http://www.morphosys.com/pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on engineering the medicines of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com:
http://www.morphosys.com/

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, arYla®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

[email protected]:
mailto:[email protected]

Conference Announcement November:
http://hugin.info/130295/R/1563518/484733.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

HUG#1563518

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;


share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MORPHOSYS AG
05/24 MORPHOSYS AG : MorphoSys Announces That Its Licensee Janssen Reported Updates on..
05/24 DGAP-NEWS : MorphoSys Announces That Its Licensee Janssen Reported Updates on th..
05/24 MORPHOSYS AG : MorphoSys to Present at Three Upcoming Conferences
05/24 MORPHOSYS : to Present at Three Upcoming Conferences
05/24 DGAP-NEWS : MorphoSys to Present at Three Upcoming Conferences
05/19 MORPHOSYS AG : MorphoSys Announces First Results from Phase 1 Study with Lanthip..
05/19 MORPHOSYS : Announces First Results from Phase 1 Study with Lanthipeptide MOR107..
05/19 DGAP-NEWS : MorphoSys Announces First Results from Phase 1 Study with Lanthipept..
05/18 DGAP-DD : MorphoSys AG english
05/18 MORPHOSYS AG : MorphoSys to Present Clinical Data on Proprietary Programs at Upc..
More news
Sector news : Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
05/06 Morphosys' (MPSYF) CEO Simon Moroney on Q1 2017 Results - Earnings Call Trans..
05/06 MorphoSys AG 2017 Q1 - Results - Earnings Call Slides
05/03 MorphoSys AG reports Q1 results
03/09 MorphoSys' (MPSYF) CEO Simon Moroney on Q4 2016 Results - Earnings Call Trans..
03/09 MorphoSys AG reports Q4 results
Advertisement
Financials (€)
Sales 2017 51,7 M
EBIT 2017 -45,6 M
Net income 2017 -48,2 M
Finance 2017 252 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 33,0x
EV / Sales 2018 37,4x
Capitalization 1 955 M
More Financials
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 68,6 €
Spread / Average Target 3,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Markus Enzelberger Chief Scientific Officer
Steffen Pohlenz Head-Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG36.76%2 188
INCYTE CORPORATION38.04%28 343
QUINTILES IMS HOLDINGS..10.74%18 637
LONZA GROUP AG23.45%15 409
CELLTRION, INC.--.--%10 281
SEATTLE GENETICS, INC.27.82%9 422
More Results